159 related articles for article (PubMed ID: 16082184)
21. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
[TBL] [Abstract][Full Text] [Related]
23. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
[TBL] [Abstract][Full Text] [Related]
25. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
26. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
Coliva A; Zacchetti A; Luison E; Tomassetti A; Bongarzone I; Seregni E; Bombardieri E; Martin F; Giussani A; Figini M; Canevari S
Cancer Immunol Immunother; 2005 Dec; 54(12):1200-13. PubMed ID: 15926078
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE
Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648
[TBL] [Abstract][Full Text] [Related]
28. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
[TBL] [Abstract][Full Text] [Related]
29. A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution.
Al-Ejeh F; Darby JM; Thierry B; Brown MP
Nucl Med Biol; 2009 May; 36(4):395-402. PubMed ID: 19423007
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
[TBL] [Abstract][Full Text] [Related]
31. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
32. SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.
Vaidyanathan G; White BJ; Affleck DJ; Zhao XG; Welsh PC; McDougald D; Choi J; Zalutsky MR
Bioorg Med Chem; 2012 Dec; 20(24):6929-39. PubMed ID: 23159039
[TBL] [Abstract][Full Text] [Related]
33. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
[TBL] [Abstract][Full Text] [Related]
35. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
Smith-Jones PM; Pandit-Taskar N; Cao W; O'Donoghue J; Philips MD; Carrasquillo J; Konner JA; Old LJ; Larson SM
Nucl Med Biol; 2008 Apr; 35(3):343-51. PubMed ID: 18355690
[TBL] [Abstract][Full Text] [Related]
36. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies.
Morales AA; Ducongé J; Alvarez-Ruiz D; Becquer-Viart ML; Núñez-Gandolff G; Fernández E; Caballero-Torres I; Iznaga-Escobar N
Nucl Med Biol; 2000 Feb; 27(2):199-206. PubMed ID: 10773550
[TBL] [Abstract][Full Text] [Related]
37. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability.
Morales AA; Núñez-Gandolff G; Pérez NP; Véliz BC; Caballero-Torres I; Ducongé J; Fernández E; Crespo FZ; Veloso A; Iznaga-Escobar N
Nucl Med Biol; 1999 Aug; 26(6):717-23. PubMed ID: 10587113
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
39. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
